Pinch to zoom
VRAYLAR significantly improved overall schizophrenia symptoms1-4*
Change in PANSS total score in schizophrenia studies
Study 11,2
It is unknown if the statistically significant differences observed at time points earlier than Week 6 represent clinically relevant treatment effects.
Maximum recommended dose of VRAYLAR is 6 mg/day. Doses above 6 mg daily did not appear to have additional benefit over lower doses and a dose-related increase in certain adverse reactions was observed.1
*The approval of VRAYLAR for the treatment of schizophrenia was based on the change from baseline in total score, not individual symptom measurement, on the PANSS.1
Three 6-week, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of VRAYLAR in adult patients (18-60 years old) with acute exacerbation of schizophrenia, based on DSM-IV-TR criteria. The primary statistical analyses were conducted using the LOCF approach for Study 1 and an MMRM approach for Study 2 and Study 3. In each study, the primary endpoint was the LS mean change from baseline in PANSS total score at the end of Week 6.1-4
Change in PANSS total score in schizophrenia studies
Study 21,3
Pinch to zoom
It is unknown if the statistically significant differences observed at time points earlier than Week 6 represent clinically relevant treatment effects.
Maximum recommended dose of VRAYLAR is 6 mg/day. Doses above 6 mg daily did not appear to have additional benefit over lower doses and a dose-related increase in certain adverse reactions was observed.1
*The approval of VRAYLAR for the treatment of schizophrenia was based on the change from baseline in total score, not individual symptom measurement, on the PANSS.1
Three 6-week, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of VRAYLAR in adult patients (18-60 years old) with acute exacerbation of schizophrenia, based on DSM-IV-TR criteria. The primary statistical analyses were conducted using the LOCF approach for Study 1 and an MMRM approach for Study 2 and Study 3. In each study, the primary endpoint was the LS mean change from baseline in PANSS total score at the end of Week 6.1-4
Change in PANSS total score in schizophrenia studies
Study 31,4
Pinch to zoom
It is unknown if the statistically significant differences observed at time points earlier than Week 6 represent clinically relevant treatment effects.
Maximum recommended dose of VRAYLAR is 6 mg/day. Doses above 6 mg daily did not appear to have additional benefit over lower doses and a dose-related increase in certain adverse reactions was observed.1
*The approval of VRAYLAR for the treatment of schizophrenia was based on the change from baseline in total score, not individual symptom measurement, on the PANSS.1
Three 6-week, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of VRAYLAR in adult patients (18-60 years old) with acute exacerbation of schizophrenia, based on DSM-IV-TR criteria. The primary statistical analyses were conducted using the LOCF approach for Study 1 and an MMRM approach for Study 2 and Study 3. In each study, the primary endpoint was the LS mean change from baseline in PANSS total score at the end of Week 6.1-4
Long-term maintenance treatment of schizophrenia in adults was assessed in a 92-week study of VRAYLAR1,5
Following a 20-week, open-label phase on a stable dose of VRAYLAR, patients were randomized to VRAYLAR 3–9 mg/day or placebo for a 72-week, double-blind phase.1,5
Kaplan-Meier curves for schizophrenia relapse rate over 72 weeks.1,5
Pinch to zoom
Patients on VRAYLAR showed significantly longer time to relapse vs placebo at 72 weeks1,5
3 simple takeaways from the 72-week double-blind period1,5,6
Patients remaining on VRAYLAR had a 48% lower risk of relapse vs placebo
[(hazard ratio=0.52; 95% CI: 0.33, 0.82) P=0.0039]
After one year, 35% of VRAYLAR patients relapsed vs 56% of placebo patients
Observed incidence of relapse was similar until approximately Week 6 (Day 44)
Recommended dose range of VRAYLAR is 1.5-6 mg/day. Doses above 6 mg daily did not appear to have additional benefit over lower doses and a dose-related increase in certain adverse reactions was observed.1
Relapse in the withdrawal study was defined as meeting any 1 of the following criteria: hospitalization due to worsening of schizophrenia, increase in the PANSS total score by ≥30%, increase in the CGI-S score by ≥2 points, deliberate self-injury, aggressive or violent behavior, clinically significant suicidal or homicidal ideation, or score >4 on 1 or more of the following PANSS items: delusions, conceptual disorganization, hallucination, suspiciousness or persecution, hostility, uncooperativeness, or poor impulse control.1,5
A long-term, 92-week, randomized withdrawal study that included a 20-week open-label phase and a 72-week double-blind, placebo controlled phase. Adult patients who met DSM-IV-TR criteria for schizophrenia (n=765) and who were clinically stable following 20 weeks of open-label VRAYLAR at doses of 3-9 mg/day were then randomized to receive either placebo (n=99) or VRAYLAR (n=101) at the same dose for up to 72 weeks in the double-blind phase. The primary endpoint was time to first relapse during double-blind treatment.1,5
CGI-S=Clinical Global Impression Scale-Severity; CI=confidence interval; DSM=Diagnostic and Statistical Manual of Mental Disorders; LOCF=last observation carried forward; LS=least squares; MMRM=mixed-effects model for repeated measures; PANSS=Positive and Negative Syndrome Scale; TR=text revision.